Woodline Partners’s Capricor Therapeutics CAPR Stock Holding History

Woodline Partners’s Portfolio CAPR Stock Details CAPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.34M	Buy	138,773 +1,118	+0.8%	+$33.9K	0.01%	774
2026 Q1	$4.18M	Sell	137,655 -81,431	-37%	-$2.17M	0.02%	690
2025 Q4	$6.32M	Buy	219,086 +208,969	+2,066%	+$2.73M	0.02%	570
2025 Q3	$72.9K	Sell	10,117 -231,527	-96%	-$1.7M	﹤0.01%	868
2025 Q2	$2.4M	Sell	241,644 -487,674	-67%	-$5.15M	0.01%	699
2025 Q1	$6.92M	Buy	729,318 +99,384	+16%	+$1.38M	0.05%	429
2024 Q4	$8.69M	Buy	+629,934	New	+$11M	0.06%	378
2024 Q2	–	Sell	-12,461	Closed	-$84.6K	–	569
2024 Q1	$84.6K	Sell	12,461 -897,081	-99%	-$4.34M	﹤0.01%	525
2023 Q4	$4.45M	Buy	+909,542	New	+$2.96M	0.05%	329

Other funds holding CAPR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Woodline Partners's CAPR Position: Q2 2026 in Review

Woodline Partners increased its Capricor Therapeutics (CAPR) stake by 0.81% in Q2 2026, buying an estimated $33.9K and bringing the position to 138,773 shares worth $3.34M. The position accounts for 0.01% of the portfolio, ranked #774.

Woodline Partners first reported a position in CAPR in Q4 2023 and has held it in 9 quarters since. The position peaked at $8.69M in Q4 2024. 170 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

Woodline Partners held 138,773 shares of Capricor Therapeutics worth $3.34M as of Q2 2026.
Woodline Partners bought 1,118 Capricor Therapeutics shares in Q2 2026, an estimated $33.9K.
Capricor Therapeutics made up 0.01% of Woodline Partners's portfolio in Q2 2026, its #774 holding.
Woodline Partners first reported a position in Capricor Therapeutics in Q4 2023 and has held it in 9 quarters since.
Woodline Partners's Capricor Therapeutics position peaked at $8.69M in Q4 2024.
170 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.